Role of ADCs in HER2-Mutated NSCLC

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Related Keywords

,Evolving Treatment Landscape ,Non Small Cell Lung Cancer ,Nsclc ,Her2 Nsclc ,Her2 Non Small Cell Lung Cancer ,Her2 Mutated Nsclc ,Sadc ,Antibody Drug Conjugates ,Treatment Guidelines ,Trastuzumab Deruxtecan ,Ther2 ,Immunotherapy ,